Le notizie dalla Borsa Italiana del ocular-therapeutix-highlights-exceptional-axpaxli-sol-1-enrollment-and-plans-for-repeat-dosing-study-sol-r-in-wet-amd-at-investor-day-along-with-positive-48-week-data-from-helios-npdr-study-2243252


Condividi